We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


High-Quality Vaccine Development Powered by Quality Control Using Agilent Fragment Analyzer System

One result of the Covid-19 pandemic has been an increased awareness of RNA-based vaccines and the speed at which they can be produced for disease outbreaks. Currently, the only approved RNA therapeutics are the Covid-19 vaccines, however, RNA is being investigated for other non-Covid prophylactic vaccines, therapeutics, and therapeutic vaccines.

One way to produce the RNAs required for these new vaccines and therapeutics is in vitro transcription (IVT). When producing any IVT RNA, quality control of the RNA is essential to ensure that the product is the correct length, does not contain contaminants or degradation products, and verify the absence of the DNA template used for IVT RNA production.

During this talk we discuss:

  • IVT RNA production
  • Accurate and precise mRNA analysis